332 related articles for article (PubMed ID: 18424722)
1. Reovirus activates human dendritic cells to promote innate antitumor immunity.
Errington F; Steele L; Prestwich R; Harrington KJ; Pandha HS; Vidal L; de Bono J; Selby P; Coffey M; Vile R; Melcher A
J Immunol; 2008 May; 180(9):6018-26. PubMed ID: 18424722
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.
Prestwich RJ; Errington F; Steele LP; Ilett EJ; Morgan RS; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
J Immunol; 2009 Oct; 183(7):4312-21. PubMed ID: 19734207
[TBL] [Abstract][Full Text] [Related]
3. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.
Steele L; Errington F; Prestwich R; Ilett E; Harrington K; Pandha H; Coffey M; Selby P; Vile R; Melcher A
Mol Cancer; 2011 Feb; 10():20. PubMed ID: 21338484
[TBL] [Abstract][Full Text] [Related]
4. Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities.
Massa C; Seliger B
J Immunol; 2013 Apr; 190(7):3328-37. PubMed ID: 23447683
[TBL] [Abstract][Full Text] [Related]
5. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.
Parrish C; Scott GB; Migneco G; Scott KJ; Steele LP; Ilett E; West EJ; Hall K; Selby PJ; Buchanan D; Varghese A; Cragg MS; Coffey M; Hillmen P; Melcher AA; Errington-Mais F
Leukemia; 2015 Sep; 29(9):1799-810. PubMed ID: 25814029
[TBL] [Abstract][Full Text] [Related]
7. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
[TBL] [Abstract][Full Text] [Related]
9. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.
Prestwich RJ; Ilett EJ; Errington F; Diaz RM; Steele LP; Kottke T; Thompson J; Galivo F; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
Clin Cancer Res; 2009 Jul; 15(13):4374-4381. PubMed ID: 19509134
[TBL] [Abstract][Full Text] [Related]
10. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
[TBL] [Abstract][Full Text] [Related]
11. NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients.
Lapenta C; Donati S; Spadaro F; Castaldo P; Belardelli F; Cox MC; Santini SM
J Immunol; 2016 Aug; 197(3):795-806. PubMed ID: 27357153
[TBL] [Abstract][Full Text] [Related]
12. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.
Prestwich RJ; Errington F; Ilett EJ; Morgan RS; Scott KJ; Kottke T; Thompson J; Morrison EE; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
Clin Cancer Res; 2008 Nov; 14(22):7358-66. PubMed ID: 19010851
[TBL] [Abstract][Full Text] [Related]
13. Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT.
Holmes TD; Wilson EB; Black EV; Benest AV; Vaz C; Tan B; Tanavde VM; Cook GP
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):E5688-96. PubMed ID: 25512551
[TBL] [Abstract][Full Text] [Related]
14. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions.
Gerosa F; Gobbi A; Zorzi P; Burg S; Briere F; Carra G; Trinchieri G
J Immunol; 2005 Jan; 174(2):727-34. PubMed ID: 15634892
[TBL] [Abstract][Full Text] [Related]
15. Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity.
Gujar SA; Marcato P; Pan D; Lee PW
Mol Cancer Ther; 2010 Nov; 9(11):2924-33. PubMed ID: 20978162
[TBL] [Abstract][Full Text] [Related]
16. Prostate carcinoma cells LNCaP and glucan cooperate in induction of cytokine synthesis by dendritic cells: effect on natural killer cells and CD4+ lymphocytes activation.
Donini M; Marongiu L; Fontana E; Dusi S
Prostate; 2012 Apr; 72(5):566-76. PubMed ID: 21796650
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin augments human DC IL-12p70 and IL-27 secretion to promote allogeneic Type 1 polarization modulated by NK cells.
Macedo C; Turnquist HR; Castillo-Rama M; Zahorchak AF; Shapiro R; Thomson AW; Metes D
Am J Transplant; 2013 Sep; 13(9):2322-33. PubMed ID: 24034707
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.
Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA
Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804
[TBL] [Abstract][Full Text] [Related]
19. NK cell regulation of T cell-mediated responses.
Zingoni A; Sornasse T; Cocks BG; Tanaka Y; Santoni A; Lanier LL
Mol Immunol; 2005 Feb; 42(4):451-4. PubMed ID: 15607797
[TBL] [Abstract][Full Text] [Related]
20. Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells.
Tomihara K; Kato K; Masuta Y; Nakamura K; Tanaka T; Hiratsuka H; Hamada H
Int J Cancer; 2007 Apr; 120(7):1491-8. PubMed ID: 17205529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
